A first-of-its-kind treatment now approved for adults with moderate to severe plaque psoriasis*
*BIMZELX is the only FDA-approved biologic that selectively inhibits the 2 immune system proteins IL-17A & IL-17F (interleukins), key drivers of inflammation.
In combined clinical trials†:
In 16 weeks, nearly 9 out of 10 people saw 90% clear skin, and were rated clear or almost clear.‡
‡88% of BIMZELX patients saw 90% skin clearance, and were rated clear or almost clear, at 16 weeks vs 3% of placebo patients.
In 16 weeks, more than 6 out of 10 people saw 100% clear skin.§
§63% of BIMZELX patients saw 100% skin clearance at 16 weeks vs 1% of placebo patients.
†Results above are from the 320 mg dose of BIMZELX, given as 2 separate injections under the skin of 160 mg each every 4 weeks for the first 16 weeks followed by every 8 weeks thereafter. Results may vary. Every person responds to treatment differently.
A uniquely personal approach to resources and support
From the first dose,
eligible commercially insured patients pay $15 or less‖
A Nurse Navigator dedicated
to you from day one¶
Medication shipment and
insurance status tracking
‖For eligible commercially insured patients only. Eligible patients who have a delay or denial of coverage may pay as little as $15 per dose of BIMZELX® for up to two years or until the patient’s commercial insurance plan approves coverage, whichever comes first. Please see full eligibility and terms.
¶Nurse Navigators do not provide medical advice and will refer you to your healthcare professional for any treatment-related questions.
Stay in the know
BIMZELX Bridge: Eligible patients must be 18 years of age or older with commercial insurance and a valid prescription consistent with FDA-approved product labeling for BIMZELX® (bimekizumab-bkzx). Eligible patients may pay as little as $15 per dose of BIMZELX for up to two years or until the patient’s commercial insurance plan approves coverage for the drug, whichever comes first. Program is not available (1) to patients whose prescriptions are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, or any other federal- or state-funded health care programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), (2) where a patient’s insurance covers the drug, (3) to uninsured or cash-paying patients, or (4) where otherwise prohibited by law. Product shall be dispensed pursuant to program rules and federal and state laws. Patients may be asked to re-verify insurance coverage status during participation in the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. This program cannot be combined with any other savings, free trial, or similar offer for the specified prescription. The patient, or healthcare provider on the patient’s behalf, must not submit any claim for reimbursement for product provided under this program to any third-party payer. UCB reserves the right to end or amend this program without notice.
For initial enrollment into the program, the patient must be experiencing a delay in, or have been denied, coverage for BIMZELX by their commercial insurance plan. To maintain eligibility in the program, the following are required: (1) a prior authorization request has been submitted and/or coverage remains unavailable for the patient; and (2) if the prior authorization is denied by the payer, the prescriber must submit an appeal within the first sixty (60) days of the prior authorization denial and a prior authorization must be submitted every six (6) months thereafter or documentation as may otherwise be required by the payer.
BIMZELX Savings: Eligible patients may pay $5 per dose. Available to individuals 18 years of age or older with commercial insurance coverage with a valid prescription consistent with FDA-approved product labeling for BIMZELX® (bimekizumab-bkzx). Not valid (1) for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, or any other federal- or state-funded healthcare programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), (2) where a patient’s commercial insurance plan reimburses for the entire cost of the drug, (3) for uninsured or cash paying patients, or (4) where otherwise prohibited by law. Product shall be dispensed pursuant to program rules and federal and state laws. The value of the program is exclusively for the benefit of patients and is intended to be credited in full towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance and deductibles. Patient may not seek reimbursement for the value of this program from other parties, including third-party payers (ie, any health insurance program or plan, or public payers like Medicare, Medicaid, Medigap, TRICARE, VA, and DoD). Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the program. This program cannot be combined with any other savings, free trial, or similar offer for the specified prescription. UCB reserves the right to amend or end this program at any time without notice.
IMPORTANT SAFETY INFORMATION:
What is the most important information I should know about BIMZELX® (bimekizumab-bkzx)?
BIMZELX is a medicine that affects your immune system. BIMZELX may increase your risk of having serious side effects, including:
Indication: BIMZELX® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet light alone or with pills (phototherapy).